oruka therapeutics inc - ORKA
ORKA
Close Chg Chg %
50.43 2.88 5.71%
Closed Market
53.31
+2.88 (5.71%)
Volume: 1.64M
Last Updated:
Apr 2, 2026, 4:00 PM EDT
Company Overview: oruka therapeutics inc - ORKA
ORKA Key Data
| Open $49.03 | Day Range 49.00 - 53.56 |
| 52 Week Range 5.49 - 53.56 | Market Cap $2.64B |
| Shares Outstanding 49.54M | Public Float 41.81M |
| Beta -0.61 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$2.32 |
| Yield 0.00% | Dividend $1.61 |
| EX-DIVIDEND DATE Aug 29, 2024 | SHORT INTEREST N/A |
| AVERAGE VOLUME 794.93K |
ORKA Performance
| 1 Week | 19.85% | ||
| 1 Month | 61.69% | ||
| 3 Months | 88.57% | ||
| 1 Year | 580.84% | ||
| 5 Years | 18.15% |
ORKA Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
13
Full Ratings ➔
About oruka therapeutics inc - ORKA
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
ORKA At a Glance
Oruka Therapeutics, Inc.
855 Oak Grove Avenue
Menlo Park, California 94025
| Phone | 1-650-606-7910 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -105,433,000.00 | |
| Sector | Health Technology | Employees | 68 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ORKA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.149 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -8.612 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.002 |
ORKA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,550,485.294 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ORKA Liquidity
| Current Ratio | 22.366 |
| Quick Ratio | 22.366 |
| Cash Ratio | 21.923 |
ORKA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -23.836 |
| Return on Equity | -24.687 |
| Return on Total Capital | -22.25 |
| Return on Invested Capital | -24.628 |
ORKA Capital Structure
| Total Debt to Total Equity | 0.409 |
| Total Debt to Total Capital | 0.408 |
| Total Debt to Total Assets | 0.395 |
| Long-Term Debt to Equity | 0.28 |
| Long-Term Debt to Total Capital | 0.277 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Oruka Therapeutics Inc - ORKA
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| 114.00K | 111.00K | 27.00K | 83.00K | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 114.00K | 111.00K | 27.00K | 83.00K | |
Depreciation
| 114.00K | 111.00K | 27.00K | 83.00K | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +25.27% | -2.63% | -75.68% | +207.41% | |
Gross Income
| (114.00K) | (111.00K) | (27.00K) | (83.00K) | |
Gross Income Growth
| -25.27% | +2.63% | +75.68% | -207.41% | |
Gross Profit Margin
| - | - | - | - | - |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 9.73M | 7.18M | 88.10M | 121.97M | |
Research & Development
| 4.46M | 1.01M | 75.06M | 100.64M | |
Other SG&A
| 5.26M | 6.17M | 13.04M | 21.33M | |
SGA Growth
| -49.45% | -26.13% | +1,126.11% | +38.45% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 755.00K | - |
EBIT after Unusual Expense
| (10.60M) | (7.30M) | (88.12M) | (122.05M) | |
Non Operating Income/Expense
| 670.00K | 1.96M | 5.87M | 16.62M | |
Non-Operating Interest Income
| 675.00K | 1.96M | 5.86M | 16.63M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | 1.47M | - |
Interest Expense Growth
| - | - | - | -100.00% | - |
Gross Interest Expense
| - | - | - | 1.47M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (9.93M) | (5.34M) | (83.72M) | (105.43M) | |
Pretax Income Growth
| +48.63% | +46.21% | -1,468.16% | -25.93% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (9.93M) | (5.34M) | (83.72M) | (105.43M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (9.93M) | (5.34M) | (83.72M) | (105.43M) | |
Net Income Growth
| +48.63% | +46.21% | -1,468.16% | -25.93% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (9.93M) | (5.34M) | (83.72M) | (105.43M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (9.93M) | (5.34M) | (83.72M) | (105.43M) | |
EPS (Basic)
| -8.2658 | -4.4443 | -4.9867 | -2.3114 | |
EPS (Basic) Growth
| +50.43% | +46.23% | -12.20% | +53.65% | |
Basic Shares Outstanding
| 1.20M | 1.20M | 16.79M | 45.61M | |
EPS (Diluted)
| -8.2658 | -4.4443 | -4.9867 | -2.3114 | |
EPS (Diluted) Growth
| +50.43% | +46.23% | -12.20% | +53.65% | |
Diluted Shares Outstanding
| 1.20M | 1.20M | 16.79M | 45.61M | |
EBITDA
| (9.73M) | (7.18M) | (88.10M) | (121.97M) | |
EBITDA Growth
| +49.45% | +26.13% | -1,126.11% | -38.45% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 64.917 | |
| Number of Ratings | 13 | Current Quarters Estimate | -0.562 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | -2.354 | |
| Last Quarter’s Earnings | -0.52 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.85 | Next Fiscal Year Estimate | -2.738 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 11 | 11 | 11 | 11 |
| Mean Estimate | -0.56 | -0.60 | -2.35 | -2.74 |
| High Estimates | -0.45 | -0.47 | -1.92 | -1.72 |
| Low Estimate | -0.71 | -0.79 | -3.16 | -3.69 |
| Coefficient of Variance | -15.94 | -19.40 | -18.96 | -24.67 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 12 | 12 | 13 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Oruka Therapeutics Inc - ORKA
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Oruka Therapeutics Inc - ORKA
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 18, 2026 | Paul T. Quinlan General Counsel | 31,767 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.3 per share | 1,311,977.10 |
| Mar 18, 2026 | Lawrence O. Klein Chief Executive Officer; Director | 927,309 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.3 per share | 38,297,861.70 |
| Mar 18, 2026 | Joana Goncalves Chief Medical Officer | 37,518 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $6.84 per share | 256,623.12 |
| Mar 18, 2026 | Joana Goncalves Chief Medical Officer | 41,018 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $7.8 per share | 319,940.40 |
| Mar 18, 2026 | Joana Goncalves Chief Medical Officer | 38,097 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $40.11 per share | 1,528,070.67 |
| Mar 18, 2026 | Joana Goncalves Chief Medical Officer | 35,195 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.2 per share | 1,450,034.00 |
| Mar 18, 2026 | Joana Goncalves Chief Medical Officer | 34,018 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.94 per share | 1,426,714.92 |
| Mar 18, 2026 | Joana Goncalves Chief Medical Officer | 33,377 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.3 per share | 1,378,470.10 |
| Mar 18, 2026 | Joana Goncalves Chief Medical Officer | 214,563 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 18, 2026 | Joana Goncalves Chief Medical Officer | 185,992 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 18, 2026 | Arjun Agarwal Senior Vice President, Finance | 18,863 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.3 per share | 779,041.90 |
| Mar 18, 2026 | Laura Sandler Chief Operating Officer | 236,984 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.3 per share | 9,787,439.20 |
| Dec 12, 2025 | Christopher Martin Director | 35,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |